Reversible defect of 123I-15-(p-iodophenyl)-9-(R,S)-methylpentadecanoic acid indicates residual viability within infarct-related area.
To evaluate the relationship between the reversible defect of 123I-15-(p-iodophenyl)-9-(R,S)-methylpentadecanoic acid (9MPA) and residual viability within an infarct-related area, we performed resting single photon emission computed tomography (SPECT) with 9MPA and positron emission tomography (PET) with 18F-deoxyglucose (FDG) and 13N-ammonia (NH3) in 7 patients with prior myocardial infarction. 9MPA-SPECT was obtained 2 min (early) and 50 min (delayed) after tracer injection. Tomographic images of the left ventricle were divided into 13 segments to correlate the regional uptake of each tracer. Residual viability within an infarct-related segment was confirmed by NH3- and FDG-PET. Twenty-six infarct-related segments, confirmed by NH3-PET, showed reduced uptake of 9MPA on early images. In these 26 segments, 6 showed reversible defect of 9MPA and 20 showed fixed defect on delayed images. Residual viability was present in all segments exhibiting reversible 9MPA defect and 7 segments (35%) exhibiting fixed defect (p < 0.05). The sensitivity, specificity and accuracy of reversible 9MPA defect for the detection of myocardial viability were 46%, 100%, and 73%, respectively. Myocardial clearance of 9MPA was significantly slower in non-viable segments than in ischemic but viable segments (4.9+/-5.1% vs. 10.1+/-5.3%; p < 0.05). These data suggest that a reversible 9MPA defect indicates residual viability within the infarct-related area.
Nakano
Akira
A
First Department of Internal Medicine, Fukui Medical University, Japan. anakano@fmsrsa.fukui-med.ac.jp
Yonekura
Yoshiharu
Y
Lee
Jong-Dae
JD
Shimizu
Hiromasa
H
Takahashi
Norio
N
Horikoshi
Motosaburo
M
Okura
Kiyotaka
K
Tsuchida
Tatsuro
T
Ueda
Takanori
T
D000368:Aged; D005227:Fatty Acids / Q000493:pharmacokinetics; D005260:Female; D019788:Fluorodeoxyglucose F18; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D007462:Iodobenzenes / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000000981:diagnostic imaging*; D017682:Myocardial Stunning / Q000000981:diagnostic imaging* / Q000209:etiology / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D011859:Radiography; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012016:Reference Values
D005227:Fatty Acids; D007462:Iodobenzenes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C067799:4-iodophenyl-9-methylpentadecanoic acid